






San Diego Skilled Nursing Facility Infection Prevention Collaborative

Grow - Collaborate - Succeed



Coordinated by the County of San Diego Healthcare-Associated Infections (HAI) Program

Reminders







Recording is on!



PHS.HAI.HHSA@ sdcounty.ca.gov



Keep your lines muted



Participate in the polls and chat



Use the chat box for questions



Slides will be emailed



Type into the chat your:

- Name
- Title

For internal use only. 1961 by distribution.



Land Acknowledgement





nfections



Public Health Services would like to begin by acknowledging the Indigenous Peoples of all the lands that we are on today. While we are meeting on a virtual platform, I would like to take a moment to acknowledge the importance of the lands, which we each call home. We respectfully acknowledge that we are on the traditional territory of the Kumeyaay. We offer our gratitude to the First Nations for their care for, and teachings about, our earth and our relations. May we honor those teachings. **Associated**

For internal use only. Not for distribution.

Agenda





Welcome

General Updates

Announcements

Featured Topic: "The IP's Role in Preventing Antimicrobial Resistance"

Next Collaborative



SNF IP Email List



Infection Prevention Week









CAHAN Alerts







To: CAHAN San Diego Participants

Date: September 9, 2024
From: Public Health Services

Health Advisory: Detection of Highly Pathogenic Avian Influenza (HPAI) A(H5N1) in California dairy cattle

Key Messages

- Avian influenza A(H5N1) has been confirmed in cows at three California dairies located in the Central Valley.
- Healthcare providers should consider avian influenza A(H5N1) in persons with acute respiratory symptoms and/or conjunctivitis and recent exposure to animals suspected or confirmed to have avian influenza.
- Healthcare providers and clinical laboratories should immediately report cases of known or suspected avian influenza (H5N1) to the County Epidemiology Unit by calling 619-692-8499 (Monday-Friday 8 AM-5 PM) or 858-565-5255 (after hours and holidays).













To: CAHAN San Diego Participants

Date: September 13, 2024 From: Public Health Services


Health Advisory: Cross-border pollution in the Tijuana River Valley and potential health effects

Key Messages


- Higher than usual levels of hydrogen sulfide gas have been reported in the vicinity of Tijuana River Valley likely
 due to increased sewage flows in the Tijuana River and exacerbated during the recent heat wave.
- Hydrogen sulfide emits a strong, foul, "rotten egg" odor and some exposed persons may develop short-term symptoms such as headaches and irritation in the eyes, nose, throat, and lungs.
- Hydrogen cyanide gas has also been reported at very low levels and detection of hydrogen cyanide may be the
 result of hydrogen sulfide cross sensitivity when using certain types of sensors.
- Use of air purifiers and odor controlling filters in air conditioning/HVAC systems may provide relief and conducting outdoor activities indoors when odors are particularly bothersome.
- Healthcare providers are encouraged to share:
 - The <u>South Region Illness Concerns webpage</u> with the patients where information on sewage safety and dealing with odors are available.
 - The San Diego Air Pollution Control District (APCD) <u>complaint map</u>, so sensitive patients can avoid areas with a high volume of odor complaints.




Respiratory Virus Update



^{*}In residential congregate settings



Respiratory Virus Update



For internal use only. Not for distribution.

BOOSTING PROTECTION IN LONG-TERM CARE THROUGH **RESPIRATORY VACCINATIONS**

VIRTUAL SUMMIT



Wednesday, October 23 10:30 AM - 12:00 PM, via Zoom

Join Us!

Keeping our residents safe from COVID, Flu, and RSV starts now!

Join us for a virtual webinar on the importance of vaccinations and infection prevention strategies in skilled nursing, long-term care, and congregate care facilities, as well as other programs serving older adults.

Register Here



https://bit.l y/3TBjwo5

Nurse CE Credit

Provider approved by California Board of Registered Nursing Provider CEP17194 for 1.5 contact hours

Number 101840

SPEAKERS

Dr. Pia Pannaraj, MD, MPH University of California San Diego

Mara Rauhauser, BSN, RN, PHN Healthcare-Associated Infections Program, County of San Diego HHSA

Dr. Karl Steinberg, MD, CMD, **HMDC**

California Association of Long Term Care Medicine

Dr. Lilia Xu, PharmD 986 Pharmacy





Registration is required!













County/CDPH Briefings





- CDPH/HSAG SNF IP Webinars:
 - Bi-monthly 4th Wednesday @ 3PM-4PM
 - Next webinar is on <u>9/25/24</u>
- County LTC Sector COVID Monthly Telebriefing:
 - Bi-monthly 4th Thursday @ 2PM-3PM
 - Next briefing is on <u>9/26/24</u>
- NHSN & HAI Nursing Home Office Hours:
 - Monthly 3rd Tuesday @11:30AM-12:30PM
 - Next session is <u>10/15/24</u>
- HSAG/CalTCM Vaccine Office Hours:
 - 2nd and 4th Thursdays monthly at 12PM-1PM
 - Next session is <u>10/10/24</u>





Contact Hour Instructions

Ensure

Ensure your full name identifies you on Teams

Enjoy

Enjoy the full presentation


Complete

Complete the post-evaluation

Presenters







Raymond Chinn, MD, FIDSA, FSHEA

Medical Consultant

County of San Diego

Healthcare-Associated Infections Program



Mara Rauhauser, BSN, RN, PHN, CIC Senior Public Health Nurse County of San Diego Healthcare-Associated Infections Program



Objectives





After attending this training, the participant will be able to:

- 1. Explain the difference between diagnostic and antimicrobial stewardship.
- 2. List 3 common myths associated with diagnosing urinary tract infections (UTI).
- 3. Describe the use of the Loeb criteria for initiation of antimicrobial therapy for presumptive UTI.
- 4. Describe the infection preventionists' role in antimicrobial stewardship.



Antimicrobial Resistance: Pieces of the Puzzle





Infection Prevention and Control Measures

- Surveillance
- Communication
- Cleaning and disinfection
- Cohorting
- Development of decolonization strategies

Antimicrobial Stewardship

- Diagnostic stewardship
- Best practice antimicrobial use (people, animals and agricultural)
- Alternate treatment strategies

Laboratory Capacity

Appropriate testing

About Antimicrobial Resistance | Antimicrobial Resistance | CDC

For internal use only. Not for distribution.







1. Explain the difference between diagnostic and antimicrobial stewardship.

- 2. List 3 common myths associated with diagnosing urinary tract infections (UTI).
- 3. Describe the use of the Loeb criteria for initiation of antimicrobial therapy for presumptive UTI.
- 4. Describe the infection preventionists' role in antimicrobial stewardship.



Assumptions





- Urinary tract infections (UTI) are commonly diagnosed health care
- Most UTIs are diagnosed inappropriately in patients without signs or symptoms of infection (asymptomatic bacteriuria - ASB).
- ASB leads to inappropriate antibiotic prescribing
 - Antimicrobial resistance a significant number originates from urinary isolates
 - Healthcare-associated infections
 - Adverse drug events












Asymptomatic Bacteriuria





Asymptomatic bacteriuria (ASB) is the presence of bacteria in the urine, with or without pyuria (urine WBC), in the **absence** of signs or symptoms of urinary tract infection (UTI) or other systemic signs or symptoms of infection.





What are the Differences between Diagnostic and Antimicrobial Stewardship (ASP)?





Is one better than the other?

Diagnostic Stewardship

("WHEN") refers to the process of modifying ordering, performing, or reporting diagnostic test results to improve the accuracy of clinical diagnosis through decreasing inappropriate detection, treatment of asymptomatic bacteriuria, and intervention. "The culture of NOT culturing"

Antimicrobial (Antibiotic)
Stewardship

("WHAT") the right drug, at the right dose, for the right duration (3Ds) and, using the best route of administration.

Infect Dis Clin North Am. 2024 Jun;38(2):255-266. doi: 10.1016/j.idc.2024.03.004. Epub 2024 Apr 4. PMID: 38575490. <u>Drugs Context.</u> 2023; 12: 2022-9-5.







- 1. Explain the difference between diagnostic and antimicrobial stewardship.
- 2. List 3 common myths associated with diagnosing urinary tract infections (UTI).
- 3. Describe the use of the Loeb criteria for initiation of antimicrobial therapy for presumptive UTI.
- 4. Describe the infection preventionists' role in antimicrobial stewardship.



UTI Diagnosis in SNF Residents: Top 5 Myths







Myth 1:

Urine cloudy and smells bad

No Symptoms = **NOT** a UTI

Myth 2: Abnormal urine studies

- Bacteria or positive for nitrates (for bacteria) in urine
- WBCs or positive leukocyte esterase (for WBCs) in urine
- Positive urine culture

No Symptoms = **NOT** a UTI

Adapted from: Schulz L, Hoffman RJ, Pothof J, Fox B. Top Ten Myths Regarding the Diagnosis and Treatment of Urinary Tract Infections. *J Emerg Med*. 2016;51(1):25-30. doi:10.1016/j.jemermed.2016.02.009



UTI Diagnosis in SNF Residents: Top 5 Myths





Myth 3:

Residents with bacteria in urine should be treated to prevent a UTI

False

Myth 4

The presence of yeast or *Candida* in the urine, especially in residents with a catheter should be treated for Candida UTI

False; treatment indicated only if candiduria suggests systemic infection

Myth 5

Falls and acute altered mental status changes in residents are usually caused by UTI



False; if signs or symptoms are absent: look for other causes first

Adapted from: Schulz L, Hoffman RJ, Pothof J, Fox B. Top Ten Myths Regarding the Diagnosis and Treatment of Urinary Tract Infections. *J Emerg Med*. 2016;51(1):25-30. doi:10.1016/j.jemermed.2016.02.009



ABCs of Delirium





IDENTIFYING DELIRIUM

ABCs OF IDENTIFICATION

Acute/subacute



Behavioral disturbance

· Restless, agitated, combative

Changes in consciousness

· Jittery, drowsy, difficult to arouse

CAUSES OF DELIRIUM

- Sleep deprivation
- Dehydration
- Medications
 - COMMON SYMPTOMS
- Drowsiness or agitation
- Refusing therapy/meals
- Refusing medications

 Arguing with staff or family

Immobility

Pain

- members
- Hallucinating
- Wandering off







TREATING AND PREVENTING DELIRIUM

1. MODIFY ENVIRONMENT

- · Orient often-time, date, place
- Provide calendar/clock in room
- Surround with familiar faces

2. PROMOTE NORMAL SLEEP

- Reduce noise, dim lights
- Promote sleep at night and activity during day

3. CORRECT SENSORY DEFICITS

- Eveglasses
- Hearing aids
- Pain management
- Good lighting

4. ENHANCE DAYTIME ACTIVITIES

- · Cognitive stimulation—word games, crossword puzzles, current events discussion
- Encourage physical/occupational therapy
- Active while awake: only sleep at night
- MOBILIZE

5. PREVENT DEHYDRATION

- · Small sips of water throughout the day
- Encourage good nutrition—supplement if necessary with smoothies or protein drinks
- Address constipation

Take Away

- Delirium is one possible symptom of UTI, but may be due to many other causes other than infection...
- Asymptomatic bacteriuria and delirium are independently common in the elderly

https://www.ahrq.gov/sites/default/files/wysi wyg/antibiotic-use/long-term-care/poster-4x6-delirium.pdf















- 1. Explain the difference between diagnostic and antimicrobial stewardship.
- 2. List 3 common myths associated with diagnosing urinary tract infections (UTI).
- 3. Describe the use of the Loeb criteria for initiation of antimicrobial therapy for presumptive UTI.
- 4. Describe the infection preventionists' role in antimicrobial stewardship.



To Enhance Diagnostic Stewardship: Using the Loeb Criteria





Minimum criteria to start antibiotics for urinary tract infections

Question:

Loeb vs McGeer Criteria: What is the difference?

Answer:

- The Loeb criteria is used to assess whether antibiotics should be started in a given **clinical** situation.
- The McGeer criteria are used to assess whether a resident has a healthcare-associated infection and is used for **surveillance** purposes



Components of the Loeb Criteria: Indwelling Urinary Catheter vs. No Catheter





LOEB CRITERIA FOR INITIATION OF ANTIBIOTIC THERAPY FOR URINARY TRACT INFECTIONS

Indwelling Urinary Catheter (foley or suprapubic)

+ at least 1 of the following:



**Delirium - disturbance of consciousness with reduced ability to focus, shift, or sustain attention.

Foul-smelling and/or cloudy urine is **NOT** a valid indication for initiation of antibiotics.





Symptoms of urgency, frequency, or incontinence w/o dysuria and absents of systemic symptoms can wait for urine culture results prior to antibiotic initiation. For internal use only. Not for distribution.



Components of the Loeb Criteria: Indwelling Urinary Catheter vs. No Catheter






LOEB CRITERIA FOR INITIATION OF ANTIBIOTIC THERAPY
FOR URINARY TRACT INFECTIONS

Indwelling Urinary
Catheter
(foley or suprapubic)

+ at least 1 of the following:



Foul-smelling and/or cloudy urine is NOT a valid indication for initiation of antibiotics.

focus, shift, or sustain attention.





Components of the Loeb Criteria: Indwelling Urinary Catheter vs. No Catheter





LOEB CRITERIA FOR INITIATION OF ANTIBIOTIC THERAPY
FOR URINARY TRACT INFECTIONS



Symptoms of urgency, frequency, or incontinence w/o dysuria and absents systemic symptoms can wait for urine culture results prior to antibiotic initiation.







- 1. Explain the difference between diagnostic and antimicrobial stewardship.
- 2. List 3 common myths associated with diagnosing urinary tract infections (UTI).
- 3. Describe the use of the Loeb criteria for initiation of antimicrobial therapy for presumptive UTI.
- 4. Describe the infection preventionists' role in antimicrobial stewardship.



Narrowing the Focus to the Urinary Tract





The role of the Infection preventionist

Educator

- Dispel the myths associated with the diagnosis of urinary tract infection
- Promote the use of the Loeb criteria among the nursing staff. This is helpfully when contacting
 physicians regarding test results and preempting use of antibiotics. Loeb criteria has application in
 other potential infectious situations

Surveillance

- Review the number of cases of probable UTI that are asymptomatic bacteriuria with the MDS coordinator who report data to CMS – Why this is not adequate
- Complete infection tracker; this is started upon initiation of antibiotics and records signs/symptoms
- Obtain the number of urine cultures done over time
- Interact with the Clinical Pharmacist and/or medical director



Reporting to the Centers for Medicare and Medicaid (CMS)





Minimum Data Set (MDS) Coding Requirements

To code a urinary tract infection (UTI) on an MDS 3.0, the following criteria must be met:

- A physician-documented UTI diagnosis within the last 30 days
- Evidence-based criteria for a UTI, such as McGeer, NHSN, or Loeb
- Significant laboratory findings
- Current medication or treatment for a UTI within the last 30 days

Surveillance limited by:

- Only reported for long-term residents (> 100 days)
- Ability to choose dates for surveillance



Narrowing the Focus to the Urinary Tract





The role of the Infection preventionist

Educator

- Dispel the myths associated with the diagnosis of urinary tract infection
- Promote the use of the Loeb criteria among the nursing staff. This is helpfully when contacting
 physicians regarding test results and preempting use of antibiotics. Loeb criteria has application
 in other potential infectious situations

Surveillance

- Review the number of cases of probable UTI that are asymptomatic bacteriuria with the MDS coordinator who report data to CMS
- Complete infection tracker; this is started upon initiation of antibiotics and records signs/symptoms
- Obtain the number of urine cultures done over time
- Interact with the Clinical Pharmacist and/or medical director



Infection Tracker





A means to track the number of urinary tract infections and cases of asymptomatic bacteriuria over time

									Antimicrobial Stewardship Program Antibiotic Tracking Sheet																			
atient	MRN	Roor		Prescribing MD/NP	Symptoms exhibited	Temp ±2 1 hr apart	vital signs (HR,RR, bp,02)	WBC WBC	Hx resistant orgs (MRSA, ESBL, CRE, MDRO)	Antibiotic ordered	Antibiotic dose	start	10.	Indication or site of inf	Catheter			Changes to therapy		Day 3 (48– 72hr) follow-up date	Patient status	Site(s)	UA who if	Organism (s) cultured	review!	Interventions	New orders	Initials
loe, Jane	323223	202	2 75	Oen	dysuria, frequency, AMS, diaphoretic	100.6 101.0	HR 126, RR 20 bp 149/89, 02 96	14.1 >100	MRSA + nares	Rocephin	2g iv q24h	nła	7 days	UTI	suprapubi c			probiotic added	cc RN	12/10/2020		Blood Urine	>100,000	negative P. mirabilis		De-escalation to	Changed to po Ceftin 500mg bid x 5d (7d total abx)	dh RPr
		-				+																						+
																												\perp
		₩				-																						+
		 																										+-
		-	-																									+
		\vdash	1																									+-
		_																										+
		-				1																						+
						+																						+-
	-	-	1																									+

Pointclickcare (PCC) EMR with Infection Tracker



Narrowing the Focus to the Urinary Tract





The role of the Infection preventionist

Educator

- Dispel the myths associated with the diagnosis of urinary tract infection
- Promote the use of the Loeb criteria among the nursing staff. This is helpfully when contacting
 physicians regarding test results and preempting use of antibiotics. Loeb criteria has application in
 other potential infectious situations

Surveillance

- Review the number of cases of probable UTI that are asymptomatic bacteriuria with the MDS coordinator who report data to CMS
- Complete infection tracker; this is started upon initiation of antibiotics and records signs/symptoms
- Obtain the number of urine cultures done over time
- Interact with the Clinical Pharmacist and/or medical director




Urine Culture Surveillance as a Measure of Diagnostic Stewardship





Using Resident Days as Denominator







For internal use only. Not for distribution.

Narrowing the Focus to the Urinary Tract





The role of the Infection preventionist

Educator

- Dispel the myths associated with the diagnosis of urinary tract infection
- Promote the use of the Loeb criteria among the nursing staff. This is helpfully when contacting
 physicians regarding test results and preempting use of antibiotics. Loeb criteria has application in
 other potential infectious situations

Surveillance

- Review the number of cases of probable UTI that are asymptomatic bacteriuria with the MDS coordinator who report data to CMS
- Complete infection tracker; this is started upon initiation of antibiotics and records signs/symptoms
- Obtain the number of urine cultures done over time
- Interact with the Clinical Pharmacist and/or medical director



Resources, albeit Limited





The Clinical Pharmacist, Medical Director, Quality Council

- The Clinical Pharmacist (CP) is at the SNF, generally a day/month for matters related to medications.
- Medical Director is the conduit to other attending MDs should issues with antibiotics arise
- Quality Council is a great venue to report surveillance data
 - Number of UTIs vs. ASB over time
 - MD outliers
 - Antibiotic use as related to antimicrobial resistance reported by clinical pharmacist



Summary: The Algorithm





For internal use only. Not for distribution.




Fig 2.

A suggested approach to the evaluation of an unwell older adult for suspected urinary tract infection (UTI). Reproduced with permission from Radcliffe Publishing. 14

Slide courtesy of Palomar Health ASP



Effective Communication





Strategies for Effective Internal Communication

- Consistent and accurate signage
- Education for staff, vendors, and visitors
- Collaboration of all leadership
- Ask staff for feedback to improve the system
- Regularly conducted adherence monitoring



Interfacility Communication



Effective Communication





Strategies for Effective Interfacility Communication

- Establish relationships with frequent receiving/discharging facilities
- Revise transfer process to improve effective communication
 - Use the CDPH interfacility transfer form
 - For admissions, request MDRO history and isolation status prior to transfer
 - When a miscommunication happens, review the situation and discuss with leadership to continually improve the system
- Create a partnership between the admission team and the Infection Preventionist
 - Provide education on relevant organisms and types of precautions needed

 <u>Interfacility Communication</u>





CDPH Interfacility Transfer form





The HAI Program strongly recommends communicating the information included in the Interfacility Transfer form by phone, in advance of transfer, for patients with the following high-priority multidrug-resistant organisms (MDRO):

- •Candida auris
- •<u>Carbapenemase-producing carbapenem-resistant Acinetobacter</u> <u>baumannii, Enterobacterales, and Pseudomonas aeruginosa (CP-CRE)</u>
- •Pan-resistant MDRO (specifically, MDRO that are resistant to all antimicrobial drugs tested)

HEALTHCARE FACILITY TRANSFER FORM Jse this form for <u>all</u> transfers to an admitting healthcare facility.					ix patie
Patient Name (Last, Fir	st):				
Date of Birth:	MRN:		Transfer Date:		
Receiving Facility Nam	e (if known):				
Contact Name (optiona	ct Phone (optional):				
Sending Facility Name:	:				
Contact Name:		Conta	ct Phone:		
PRECAUTIONS					
Patient currently on precautions? If yes, check all that apply: Yes No Airborne Contact Droplet Enl				Enhanced :	Standa
Precautions in acute care so DRGANISMS (Include co	settings. opy of lab results with	h organism ID and ant		bilities.)	
Precautions in acute care so DRGANISMS (Include co Patient is <u>NOT</u> know requiring precaution	settings. The pay of lab results with the pay of lab resu	h organism ID and ant	imicrobial suscepti	bilities.) or other orga	nisms
Precautions in acute care so DRGANISMS (Include co Patient is <u>NOT</u> know	settings. The pay of lab results with the pay of lab resu	h organism ID and ant	imicrobial suscepti	bilities.) or other orga	nisms
Precautions in acute care some particular to proceed the process of the process o	pettings. ppy of lab results with n to be colonized on s (skip section) or other lab results re	h organism ID and ant r infected with any m equiring precautions	imicrobial suscepti ultidrug-resistant o record organism(s)	bilities.) or other orga), specimen s	nisms
Precautions in acute care so DRGANISMS (Include co Patient is <u>NOT</u> know requiring precaution Patient has MDRO of collection date)	pettings. ppy of lab results with n to be colonized on s (skip section) or other lab results re	h organism ID and ant r infected with any m equiring precautions	imicrobial suscepti ultidrug-resistant o record organism(s)	bilities.) or other orga), specimen s	ource,
Precautions in acute care : ORGANISMS (Include co Patient is NOT know requiring precautior Patient has MDRO o collection date) Exposed to MDRO/o	ppy of lab results with the colonized on the colonized on the colonized on the colonized or	h organism ID and ant r infected with any m equiring precautions	imicrobial suscepti ultidrug-resistant or record organism(s) of exposure if know Carbapenemase	bilities.) or other orga), specimen s	nisms
Precautions in acute care so ORGANISMS (Include co Patient is NOT know requiring precaution Patient has MDRO of collection date) Exposed to MDRO/o	settings. ppy of lab results with on to be colonized on ons (skip section) or other lab results re other (record organis Organism ris) e (C. diff)	h organism ID and ant r infected with any m equiring precautions sm(s) and last date(s)	imicrobial suscepti ultidrug-resistant or record organism(s) of exposure if know Carbapenemase	bilities.) or other orga), specimen s	ource,
Precautions in acute care so ORGANISMS (Include co Patient is NOT know requiring precaution Patient has MDRO oc collection date) Exposed to MDRO/o	settings. ppy of lab results with the colonized on its (skip section) or other lab results re	h organism ID and ant r infected with any m equiring precautions sm(s) and last date(s)	imicrobial suscepti ultidrug-resistant or record organism(s) of exposure if know Carbapenemase	bilities.) or other orga), specimen s	ource,
Precautions in acute care : ORGANISMS (Include co Patient is NOT know requiring precaution Patient has MDRO of collection date) Exposed to MDRO/of Condida auris (C. au Clostridiodes difficile Acinetobacter, multi Carbapenem-resista	ppy of lab results with the colonized on as (skip section) or other lab results result	h organism ID and ant r infected with any management of the control of the contro	imicrobial suscepti ultidrug-resistant or record organism(s) of exposure if know Carbapenemase	bilities.) or other orga), specimen s	ource,
Precautions in acute care : ORGANISMS (Include co Patient is NOT know requiring precaution Patient has MDRO of collection date) Exposed to MDRO/of Candida auris (C. au Clostridodes difficile Carbapenem-resista Pseudomonas aerug	ppy of lab results with the colonized of	h organism ID and ant r infected with any management of the control of the contro	imicrobial suscepti ultidrug-resistant or record organism(s) of exposure if know Carbapenemase	bilities.) or other orga), specimen s	ource,
Precautions in acute care : ORGANISMS (Include co Patient is NOT know requiring precautior Patient has MDRO o collection date) Exposed to MDRO/o Candida auris (C. au Clostridiodes difficile A cinetobacter, multi Carbapenem-resista Pseudomonas aerug Extended-spectrum	ppy of lab results with the total section of the colonized on the colonized on the colonized or the colonize	h organism ID and ant r infected with any management of the control of the contro	imicrobial suscepti ultidrug-resistant or record organism(s) of exposure if know Carbapenemase	bilities.) or other orga), specimen s	ource,
Precautions in acute care so ORGANISMS (Include co Patient is NOT know requiring precaution Patient has MDRO of collection date) Exposed to MDRO/of Candida auris (C. au Clostridiodes difficile Acinetobacter, multi Carbapenem-resista Pseudomonas aerug Extended-spectrum Methicillin-resistant	py of lab results with the total section of the colonized or one (skip section) or other lab results resolved (record organism or other (record organism or other lab results resolved (c. diff) drug-resistant (e.g., the colonized organism or enterpolacterales inosa, multidrug-resibeta-lactamase (ESB Staphylococcus auree)	h organism ID and ant r infected with any mequiring precautions (sm(s) and last date(s) (CRAB**) (CRE**) (ISTANT (e.g., CRPA**) L)-producer eus (MRSA)	imicrobial suscepti ultidrug-resistant or record organism(s) of exposure if know Carbapenemase	bilities.) or other orga), specimen s	ource,
Precautions in acute care : ORGANISMS (Include co Patient is NOT know requiring precaution Patient has MDRO of collection date) Exposed to MDRO/of Condida auris (C. au Clostridiodes difficie Acinetobacter, multi Carbapenem-resista Pseudomonas aerug Extended-spectrum Methicillin-resistant Vancomycin-resistant	py of lab results with the colonized on a (skip section) or other lab results (c. diff) drug-resistant (e.g., and tendence results res	h organism ID and ant r infected with any management of the control of the contro	imicrobial suscepti ultidrug-resistant or record organism(s) of exposure if know Carbapenemase	bilities.) or other orga), specimen s	ource,
Precautions in acute care: ORGANISMS (Include co Patient is NOT know requiring precaution Patient has MDRO of collection date) Exposed to MDRO/of Colostridiodes difficite Acinetobacter, multi Carbapenem-resista Pseudomonas aerug Extended-spectrum Methicillin-resistati Vancomycin-resistat No organism identifi	py of lab results with the colonized on a (skip section) or other lab results (c. diff) drug-resistant (e.g., and tendence results res	h organism ID and ant r infected with any management of the control of the contro	imicrobial suscepti ultidrug-resistant or record organism(s) of exposure if know Carbapenemase	bilities.) or other orga), specimen s	ource,
Precautions in acute care : ORGANISMS (Include co Patient is NOT know requiring precautior Patient has MDRO of collection date) Exposed to MDRO/o Candida auris (C. au Clostridiodes difficile Acinetobacter, multi Carbapenem-resista Pseudomonas aerug Extended-spectrum Methicillin-resistant Vancomycin-resistant No organism identifi Other, specify:	ppy of lab results with the colonized on as (skip section) or other lab results result	h organism ID and ant r infected with any management of the productions (sm(s) and last date(s) (sm(s) and last date(s) (CRAB**) (CRE**) (ISTANT (e.g., CRPA**) L)-producer (sus (MRSA)) creening test**)	imicrobial suscepti ultidrug-resistant or record organism(s) of exposure if know Carbapenemase	bilities.) or other orga), specimen s	ource,
Precautions in acute care: ORGANISMS (Include co Patient is NOT know requiring precaution Patient has MDRO of collection date) Exposed to MDRO/of Colostridiodes difficite Acinetobacter, multi Carbapenem-resista Pseudomonas aerug Extended-spectrum Methicillin-resistati Vancomycin-resistat No organism identifi	py of lab results with the total section of the colonized on the colonized of the colonized	h organism ID and ant r infected with any minequiring precautions (sm(s) and last date(s) (sm(s) and last date(s) (cree*) (cree*) (stant (e.g., CRPA**) L)-producer (sus (MRSA) (creening test**) (disseminated	imicrobial suscepti ultidrug-resistant or record organism(s) of exposure if know Carbapenemase	bilities.) or other orga), specimen s	ource,



Refining the MDRO Transfer Form





TRANSFER INFORMATION							
Reason for transfer:		□ N/A					
Patient has any of the following symptoms or clinical status? $\ \square$ N/A							
☐ Acute diarrhea or incontinent stool	☐ Incontinent of urine						
☐ Change in respiratory secretions	☐ Vomiting						
Change in mental status		(e.g.					
☐ Change in wound drainage (e.g. purulence)§	vascular)						
Mental Status at transfer: ☐ Alert ☐ Not alert ☐ Oriented ☐ Disoriented							
Baseline mental status: ☐ Alert ☐ Not alert ☐ Oriented ☐ Disoriented							
Preexisting conditions: □ Cloudy Urine □ Respiratory	Secretion Speech: Verbal Nonverbal						
Instructions for receiving facility:		□ N/A					
Scans or labs performed? ☐ Work-Up Attached ☐ Cultures Pending ☐ Please contact for workup							
Procedures completed during stay: Yes:	□ No	□ N/A					



What can the HAI Program do to help?







Outbreak response Support IP rounding

Interpret state/federal guidance

Support staff in-services

Support quality improvement projects

Share resources and tools






For internal use only. Not for distribution.



- Ensure your TEAMS name is your full name
- Complete by September 27th,5:00 PM
- Expect your certificate by October 15th.





Next Collaborative

November 20, 2024
11:00AM – 12:00PM

Microsoft TEAMS

Featured Topic:

Occupational Health

1 Contact Hour Offered

Submit questions or feedback about today's meeting to:

PHS.HAI.HHSA@sdcounty.ca.gov

For internal use only. Not for distribution.





Contact us at:

PHS.HAI.HHSA@sdcounty.ca.gov



The Public Health Services department, County of San Diego Health and Human Services Agency, has maintained national public health accreditation, since May 17, 2016, and was re-accredited by the Public Health Accreditation Board on August 21, 2023.



